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Abstract
Background: Invasive bacterial diseases (IBD) are a serious cause of hospitalization, sequelae and mortality. Albeit a
low incidence, an increase in cases due to H. influenzae was registered in the past 4 years and, in the Tuscany
region, an excess of cases due to N. meningitidis since 2015 is alarming. The purpose of this study is to deepen the
knowledge of IBD epidemiology in Tuscany with particular attention to temporal trends.
Methods: Tuscan residents hospitalized for IBD from January 1st 2000 to March 18th 2016 were selected from the
regional hospital discharge database based on ICD-9-CM codes. Age-specific and standardized hospitalization rates
were calculated together with case-fatality rates (CFRs). A time-trend analysis was performed; whereas, prognostic
factors of death were investigated through univariable and multivariable analyses.
Results: The average standardized hospitalization rates for invasive meningococcal diseases (IMD), invasive
pneumococcal diseases and invasive diseases due to H. influenzae from 2000 to 2016 were 0.6, 1.8, and 0.2 per
100,000, respectively. The average CFRs were 10.5%, 14.5% and 11.5% respectively with higher values in the elderly.
Older age was significantly associated with higher risk of death from all IBD. A significant reduction in
hospitalization rates for IMD was observed after meningococcal C conjugate vaccine introduction. The Annual
Percentage Change (APC) was -13.5 (95% confidence interval (CI) -22.3; -3.5) in 2005–2013 but has risen since that
period. Furthermore, a significant increasing trend of invasive diseases due to H. influenzae was observed from 2005
onwards in children 1–4 years old (APC 13.3; 95% CI 0; 28.3).
Conclusions: This study confirms changes in the epidemiology of invasive diseases due to H. influenzae and IMD.
Furthermore, attention is called to the prevention of IBD in the elderly because of the age group’s significantly
higher rate of hospitalizations and deaths for all types of IBD.
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Background
Invasive bacterial diseases (IBD) are an important public
health issue and cause a serious burden in several coun-
tries, particularly among young persons and the elderly.
The most common IBD clinical manifestations are septi-
cemia and meningitis, with the first occurring even with-
out the presence of the second, accounting together for
170,000 annual deaths worldwide [1, 2]. Meningitis is a
severe infection of the meninges and can rapidly pro-
gress from the sudden onset of non-specific symptoms
(including fever, nausea, vomiting, and neck stiffness) to
death in 24 h. As many as 20–50% of the survivors may
have permanent sequelae, such as hearing loss, amputa-
tion, or neurological and behavioral impairments [3–5].
Septicemia is a life-threatening condition that can cause
tissue damage, organ failure, and death [6]. The three
most common etiological agents of IBD are Haemophilus
influenzae, Streptococcus pneumoniae, and Neisseria
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meningitidis. They are carried asymptomatically in the hu-
man nasopharynx and transmitted by aerosol droplets or
secretions during close or lengthy contact. H. influenzae
may be non-encapsulated (non-typeable) or encapsulated
with a polysaccharide capsule. In the latter case, six sero-
types (a-f) are recognized, with H. influenzae serotype b
(Hib) being the most pathogenic. Before the availability of
Hib conjugate vaccines in the late 1990s, H. influenzae
was causing the majority of bacterial meningitis and IBD,
while it now accounts for only 2–7% of cases [7–10]. Inva-
sive diseases due to H. influenzae are most common in
children below 5 years of age and rare in adolescents and
adults [11]. With the decline of cases due to H. influenzae,
S. pneumoniae became the leading cause of IBD, especially
among children younger than 5 years of age, elderly and
people with chronic diseases or immuno-compromised
[12]. Out of 93 known S. pneumoniae serotypes, only 20–
30 are responsible for the majority of invasive pneumo-
coccal diseases (IPD) worldwide [13]. Furthermore, S.
pneumoniae is known as the leading cause of
community-acquired pneumonia, and the lethality associ-
ated with bacteriaemic pneumococcal pneumonia is 6–
20% [14]. The 7-valent pneumococcal conjugate vaccine
(PCV7) for infants and young children was licensed in
Europe in 2001, leading to a reduction in hospitalization
rates for all S. pneumoniae –related diseases in children
[15–17]. With the replacement of PCV7 with the
13-valent pneumococcal conjugate vaccine (PCV13) in
2010–2011 and the extension of vaccination to elderly
and people at risk [18], it is likely that N. meningitidis will
become a major agent of IBD worldwide, in particular if
vaccination coverage will not reach high levels. Moreover,
N. meningitidis is the only bacterium able to produce epi-
demics of meningitis. Incidence rates of invasive meningo-
coccal diseases (IMD) are generally highest in children
below 5 years of age followed by adolescents and young
adults. Thirteen serogroups of N. meningitidis can be
identified on the basis of the polysaccharide capsule but
only six are responsible for most IMD cases: A, B, C,
W135, X, and Y [2]. The distribution of these serogroups
varies geographically, likely because of differences in
population immunity and environmental factors. In
Europe, serogroup B (MenB) is the main cause of IMD,
accounting for up to 80% of cases in some countries,
followed by serogroups C (MenC) and Y (MenY) [2, 19].
With the introduction of the MenC conjugate vaccine
(MCC) in the immunization schedules of several European
countries, a significant decline in the incidence of MenC
diseases has occurred over the past 10 years [19–21].
Nowadays, in Italy, PCV13 is given, together with Hib
vaccine, in three doses within the first year of age (3, 5–
6, 11–13 months of age) [22]; whereas MCC is delivered
in a single dose at 13–15 months of age with a catch-up
at 12–14 years of age [23]. In 2014–2015, a
multicomponent MenB vaccine (4CMenB) has been
introduced and is currently given in two, three or four
doses depending on child’s age at the time of vaccin-
ation. Nevertheless, until the launch of the new National
Immunization Plan in January 2017, MenB vaccine has
been offered free of charge only in few Italian regions
[23–25]. Incidence rates for IBD are relatively low in all
Italian regions. In 2014, national incidence rates were as
follows: 0.17 per 100,000 for invasive H. influenzae
diseases, 0.27 per 100,000 for IMD, and 1.57 per 100,000
for IPD. However, an increase in the incidence rates of
invasive H. influenzae diseases was registered from 2011
[26]. Moreover, in particular in the Tuscany region, an
excess of IMD cases was registered from January 2015
onwards [27]. Health authorities responded to the
increasing number of cases with an extraordinary
vaccination campaign [28, 29].
The present study aims to study the epidemiology of IBD
in Tuscany, with particular attention to temporal trends.
For the three types of IBD, over a 16-year period, we esti-
mated: i) age-specific and standardized hospitalization rates
and their relationship with vaccination coverage; ii) age-
specific case-fatality rates (CFR); and iii) time-trends of
age-specific hospitalization rates. Additionally, prognostic
factors for death were investigated.
Methods
Study design, case definition and data collection
This is a historical cohort study conducted in Tuscany,
an Italian region with a population of 3.7 million people.
The regional hospital discharge database was accessed in
order to identify patients admitted with a diagnosis of IBD
due to N. meningitidis, S. pneumoniae or H. influenzae
from January 1st 2000 to March 18th 2016. The database
relies on the International Classification of Disease, Ninth
Revision, Clinical Modification (ICD-9-CM) system that is
currently used in Italy [30]. The project has been approved
by the Ethics Committee of the “Azienda Ospedaliero-
Universitaria Meyer” of Florence on October 4th 2010
(authorization number 2010/7880).
Eligible patients were retrospectively searched in the
regional hospital discharge database using the following
ICD-9-CM codes for primary or secondary diagnosis:
 IMD: 036.0 (meningococcal meningitis), 036.1
(meningococcal encephalopathy), 036.2
(meningococcal septicemia), 036.40 (unspecified
meningococcal carditis), 036.41 (meningococcal
pericarditis), 036.42 (meningococcal endocarditis),
036.43 (meningococcal myocarditis), 036.81
(meningococcal optic neuritis), 036.82
(meningococcal arthropathy), 036.89 (other specified
forms of meningococcal infection), and 036.9
(unspecified meningococcal infection);
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 IPD: 038.2 (pneumococcal septicemia), and 320.1
(pneumococcal meningitis);
 invasive H. influenzae diseases: 038.41 (septicemia due
to H. influenzae), and 320.0 (Haemophilus meningitis).
Hospital discharge records of eligible patients included
the following data: details of the admitting hospital, age,
gender, nationality, region of residence, date of admis-
sion, one primary and five secondary diagnoses, surgical
and other procedures, date and type of discharge. All
hospitalized patients living in Tuscany and discharged
from a Tuscan hospital, with one of the ICD-9-CM
codes described above in primary or secondary diagno-
sis, were included in the study. One day-hospitalizations
were excluded. A cross-check of data included in the
hospital discharge record of included patients was
conducted to avoid duplicates due to patients being
transferred from a hospital to another one. With re-
spect to the population at risk, the number of people
residing in Tuscany during the study period (at January
1st of each year), stratified by age and gender, was
taken from the Italian National Statistical Institute
(ISTAT) database [31]. Data on vaccination coverage of
H. influenzae (Hib), S. pneumoniae (PCV) and N.
meningitidis (MCC) at 24 months of age were searched
on the Italian Ministry of Health database and ICONA
studies [32–34].
Statistical analysis
Continuous variables were summarized using mean ±
standard deviation (SD), whereas categorical variables
were reported as absolute and relative frequencies. Stat-
istical analyses were carried out using STATA software
version 13.1 except as otherwise specified.
Descriptive analysis
Age-specific hospitalization rates (HR), stratified for type
of invasive disease, were calculated as cases per 100,000
together with 95% confidence intervals (95% CI). Resi-
dent population at January 1st of each year was used for
the calculation. Standardized hospitalization rates (SHR)
and their 95% CI were considered to compare hospitali-
zations between years. Standardization was performed
with respect to age and gender using the Italian popula-
tion (latest available data from 2016) as external weight.
95% CIs were obtained as standardized rate ± 1.96*stand-
ard error (SE), and SE was calculated with the following
Armitage and Berry formula [35]:
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
P TixN2i xK
 
ni
P
Nið Þ2
v
u
u
u
t
Ti = crude rate for each age class
Ni = size of the reference population in each age class
ni = size of the study population in each age class
K =multiplication factor (100,000).
Patients were stratified into seven age groups following
the classification adopted by the National Surveillance
System: <1, 1–4, 5–9, 10–14, 15–24, 25–64, ≥65 years of
age. Case-fatality rates (CFR) were calculated dividing
the number of deaths by the number of cases and were
presented stratified for type of invasive disease.
Time-trend analysis
Changes in overall and age-specific HRs from 2000 to
2015 were assessed by joinpoint (JP) regression accord-
ing to Kim’s method [36]. Data regarding 2016 were ex-
cluded from this analysis because they were partial. A
joinpoint represents the time point when a significant
trend change is detected. Time changes were expressed
in terms of Annual Percent Change (APC) with 95% CI.
The null hypothesis was tested using a maximum of
three changes in the slope with an overall significance
level of 0.05 divided by the number of joinpoints in the
final model. Joinpoint Regression program version 4.3.1
was used to carry out the analysis.
Health outcome analysis
Chi-square test was used to assess the relationships be-
tween the health outcome (dead, alive) and independent
variables such as: age (<5, 5–17, 18–64, ≥65 years of age),
gender, nationality (Italian, non-Italian) and Charlson
Index [37]. The Charlson Index was used as a proxy of
comorbidity and calculated according to the algorithms
developed by Quan et al. [38] looking at Enhanced
ICD-9-CM Coding in primary and secondary diagnoses.
The STATA additional software package “charlson” was
used for this calculation. Variables with p-values below
0.25 at the univariable analysis were entered in a logistic
regression model. The results were shown in terms of
Odds Ratio (OR) and 95% CI. All the analyses and models
were carried out stratifying by type of invasive disease.
Results
Descriptive analysis
A total of 1691 patients with IBD were hospitalized
between January 1st 2000 and March 18th 2016 at 52
hospitals in Tuscany region; 107 were residents outside
the region and excluded from further analysis. Among
the residents, 288 were children and adolescents
(<18 years), and 1296 were adults and elderly (≥18 years).
Additional file 1: Table S1 summarizes the study popula-
tion’s characteristics. Most children and adolescents
were admitted to the Anna Meyer Children’s University
Hospital in Florence (n = 127; 44.1%). More than half of
the hospitalizations of children and adolescents were
due to IMD (n = 153; 53.1%) followed by IPD (n = 112;
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38.9%). Children’s and adolescents’ mean age was 4.8 ±
5.2 years and the mean hospitalization length was 16 ±
15.4 days; 56.9% of them were males and 92% were Italian.
Among adults and elderly, IPD was the most common
IBD (n = 1017; 78.5%). Their mean age was 61.3 ± 18 years,
males and females were equally represented and the ma-
jority was Italian. The mean length of hospitalization was
12 ± 8.9 days. Invasive H. influenzae diseases accounted
for approximately 8% of cases in both groups. Data on
vaccination coverage at 24 months of age in Tuscany were
available for Hib from 2003 to 2015. Hib average coverage
during the study period was of 94% but two drops to 88%
were registered in 2003 and 2010. On the contrary, data
for PCV and MCC vaccination coverage were retrieved
only for 2003, 2008 and 2013–2015. Vaccination coverage
was very low in 2003 and 2008, whereas it was between
92.9 and 94% for PCV and between 87.8 and 90.9% for
MCC in 2013–2015.
More than one-quarter (n = 86; 26.1%) of the 330 hos-
pitalizations for IMD occurred in children less than 4
years of age. No child <1 year of age died, while five died
in the 1–4 years age group, yielding a CFR of 8.2% in
this age group. People from 15 to 24 and from 25 to
64 years of age accounted for almost half (n = 158;
47.9%) of IMD hospitalizations, with CFRs of 8.0% and
9.6% respectively. The highest number of deaths (11
deaths out of 42 cases) was registered in elderly
(≥65 years of age) with a CFR of 26.2%. More than half
(n = 581; 51.5%) of the 1129 hospitalizations for IPD oc-
curred in people ≥65 years of age with more than
three-quarters (n = 122; 75.3%) of all deaths due to this
infection, yielding a CFR of 21%. Similarly, almost half
(n = 61; 48.8%) of the 125 hospitalizations for invasive H.
influenzae diseases occurred in the ≥65 years age group.
All deaths for this IBD were registered in this age group
(CFR: 21.3%) except one in the 1–4 years age group
(CFR: 11.1%) (Table 1). During the whole study period,
CFR due to IMD had the lowest mean value (10.5%, min
0.0%, max 33.3%). IPD and invasive H. influenzae dis-
eases presented a mean CFR of 14.5% (min 7.8%, max
23.8%) and 11.5% (min 0.0%, max 50.0%) (Fig. 1). Table 2
reports SHRs for type of IBD and year. The mean SHR
for IMD was 0.6 per 100,000, with two peaks around 1
per 100,000 in 2004–2005 and in 2015. IPD had a mean
SHR of 1.8 per 100,000, ranging from 1.4 per 100,000 in
2010 to 2.2 per 100,000 in 2012. During the study
period, invasive H. influenzae diseases had SHRs always
below or equal to 0.3 per 100,000 (mean SHR: 0.2 per
100,000), with higher values in 2000–2005, 2012 and
2014 (Table 2). In the latter, the age-specific HRs for
children <1 year of age and from 1 to 4 years of age showed
peaks up to 7 per 100,000 children. The relationship be-
tween data on vaccination coverage and age-specific HRs
for invasive H. influenzae diseases is shown in Fig. 2. On
the contrary, the relationship between PCV and MCC vac-
cination coverage and HRs was not shown because of lack
of data.
Time-trend analysis
The joinpoint analysis by type of IBD and age group is
shown in Tables 3, 4 and 5. As far as IMD is concerned,
considering all ages, joinpoints were found in 2005 and
2013 showing a significant decreasing trend in 2005–
2013 (APC -13.4; 95% CI -22.3; -3.5; p < 0.0001) and a
positive but non-significant trend before and after this
time. No joinpoints or significant trends were shown for
children up to 9 years old. However, while infants <1 year
of age had a positive APC (APC 3.1; 95% CI -5.1; 12.1),
HRs for the 1–4 years and 5–9 years age groups tended
to decrease (APC -5.9 and -7.6 respectively). The great-
est reduction was found in the 10–14 years age group,
whose APC decreased from 7.6 (95% CI -27.7; 60.2) in
2000–2004 to -8.5 (95% CI -15.9; -0.4; p < 0.0001) after-
wards. No joinpoints were found in the other age
groups. With respect to IPD, the overall trend was stable
over time (APC 0.7; 95% CI -0.6; 2.1). Infants <1 year of
Table 1 Absolute and relative frequencies of cases and deaths, and CFRs by age group due to IBD in Tuscany from 2000 to 2016a
(N = 1584)
Age group IMD IPD Invasive H. influenzae diseases
Cases n (%) Deaths n (%) CFR Cases n (%) Deaths n (%) CFR Cases n (%) Deaths n (%) CFR
<1 year 25 (7.6) 0 (0.0) 0.0 29 (2.6) 0 (0.0) 0.0 7 (5.6) 0 (0.0) 0.0
1–4 years 61 (18.5) 5 (16.1) 8.2 52 (4.6) 0 (0.0) 0.0 9 (7.2) 1 (7.1) 11.1
5–9 years 22 (6.7) 1 (3.2) 4.5 22 (2.0) 0 (0.0) 0.0 4 (3.2) 0 (0.0) 0.0
10–14 years 22 (6.7) 0 (0.0) 0.0 5 (0.4) 1 (0.6) 20.0 2 (1.6) 0 (0.0) 0.0
15–24 years 75 (22.7) 6 (19.4) 8.0 14 (1.2) 1 (0.6) 7.1 2 (1.6) 0 (0.0) 0.0
25–64 years 83 (25.1) 8 (25.8) 9.6 426 (37.7) 38 (23.5) 8.9 40 (32.0) 0 (0.0) 0.0
≥65 years 42 (12.7) 11 (35.5) 26.2 581 (51.5) 122 (75.3) 21.0 61 (48.8) 13 (92.9) 21.3
All ages 330 (100.0) 31 (100.0) 9.4 1129 (100.0) 162 (100.0) 14.3 125 (100.0) 14 (100.0) 11.2
aData refer up to March 2016
IMD invasive meningococcal diseases, IPD invasive pneumococcal diseases, CFR case-fatality rate
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age had an overall significant decreasing trend (APC
-9.4; 95% CI -16; -2.3; p < 0.0001) (data not shown) with
a joinpoint in 2004 and an APC of -16.7 in 2004–2015
(95% CI -28; -3.6; p < 0.0001). Children from 1 to 4 years
of age also had a negative but non-significant APC
(APC -7; 95% CI -13.7; 0.2). Joinpoints were found in
the 10–14 years age group in 2002, 2009 and 2012, with
positive and negative fluctuating trends. Young adults
in the 15–24 years age group showed a joinpoint in
2003: APC changed from 95.2 (95% CI -50.5; 670.3) in
2000–2003 to -13.4 (95% CI -22.5; -3.3; p < 0.0001)
afterwards. No joinpoints were found in adults and
elderly (positive non-significant trends). For invasive H.
influenzae diseases, there was an overall decreasing but
non-significant trend (APC -1.5; 95% CI -5.3; 2.4). Join-
points were found in all age groups except for adults
and elderly. Infants <1 year of age had a significant
decreasing trend in 2000–2008 (APC -17.5; 95% CI
-30.5; -2.1; p < 0.0001) followed by an increasing but
non-significant trend. Joinpoints were found in children
from 1 to 4 years of age in 2002 and 2005: a significant
increase was seen in 2005–2015 (APC 13.3; 95% CI 0.0;
28.3; p < 0.0001). On the contrary, the trend decreased
for children 5–9 years old in 2008–2015 (APC -15.1;
95% CI -24; -5.1; p < 0.0001). In the 10–14 years age
group, joinpoints were found in 2003, 2009 and 2012,
with positive and negative fluctuating trends. Young
adults in the 15–24 years age group had an overall sig-
nificant decreasing trend (APC -3.4; 95% CI -5.5; -1.4;
p < 0.0001) (data not shown) with a joinpoint in 2003
and an APC of -19.3 in 2003–2015 (95% CI -30.4; -6.5;
p < 0.0001). An exemplary time-trend change is illus-
trated in Additional file 2: Figure S1.
Health outcome analysis
The univariable analyses showed that there were more
deaths in older patients, in females, in Italian patients,
and in patients with comorbidities. Among all deaths due
to IMD, only 9 (29%) were registered in the pediatric age
as compared to 22 (71%) in people ≥18 years of age
(p = 0.004). The same was observed for IPD (p < 0.0001)
and invasive H. influenzae diseases (p = 0.003). Age was
entered into all IBD logistic regression models and, in
light of small absolute frequencies, it was classified as
<18 years vs ≥18 years of age for IPD and as <65 years vs
≥65 years of age for invasive H. influenzae diseases.
Fig. 1 Case-fatality rates (CFRs) per type of IBD from 2000 to 2016
Table 2 Summary table of HRs (per 100,000) standardized for
age and gender
Years IMD IPD Invasive H. influenzae diseases
2000 0.552 1.505 0.246
2001 0.593 1.789 0.307
2002 0.822 1.808 0.252
2003 0.373 2.057 0.329
2004 0.953 1.780 0.285
2005 1.067 2.046 0.217
2006 0.486 1.799 0.162
2007 0.557 1.920 0.251
2008 0.488 1.896 0.063
2009 0.508 1.748 0.202
2010 0.437 1.440 0.158
2011 0.352 2.002 0.084
2012 0.381 2.170 0.281
2013 0.250 1.741 0.109
2014 0.492 1.621 0.279
2015 0.904 2.048 0.205
2016a 0.336 0.783 0.051
aData refer up to March 2016
HR hospitalization rate, IMD invasive meningococcal diseases, IPD invasive
pneumococcal diseases
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Gender was not shown to be significantly associated to
death, but it was kept in the IMD and IPD logistic regres-
sion models. Among patients who died for IPD, there
were more Italians than non-Italians (p = 0.052). Signifi-
cant associations were not found for the other two IBD,
therefore nationality was entered only into the logistic re-
gression model for IPD. As for the Charlson Index, a
smaller percentage of people without comorbidities was
observed among patients who died as compared to those
who survived. For instance, 90% of IMD patients dis-
charged alive had no comorbidities in comparison to
74.2% among who died (p = 0.014). Significant associations
were also seen in the other two IBD and Charlson Index
was entered into all models as a dichotomous variable
(presence/absence of comorbidities) (Table 6).
The final logistic regression models for type of invasive
disease are shown in Table 7. They were overall statisti-
cally significant and demonstrated that older age was a
risk factor for dying for all IBD. In particular, the IMD
model was entirely explained by the variable age, with
Fig. 2 Age-specific HRs of invasive H. influenzae diseases in children below 4 years of age and Hib vaccination coverage in Tuscan children from
2003 to 2015
Table 3 Findings of the joinpoint regression for IMD by age
group
Age group Joinpoint Years Range APC (95% CI) p-value
All age groups 2005 2000–2005 9.9 (-5.3;27.5) 0.2
2013 2005–2013 -13.4 (-22.3; -3.5) < 0.0001
2013–2015 80 (-7.3; 249.5) 0.1
<1 year No JP 2000–2015 3.1 (-5.1; 12.1) 0.4
1–4 years No JP 2000–2015 -5.9 (-11.6; 0.2) 0.1
5–9 years No JP 2000–2015 -7.6 (-14.9; 0.4) 0.1
10–14 years 2004 2000–2004 7.6 (-27.7; 60.2) 0.7
2004–2015 -8.5 (-15.9; -0.4) < 0.0001
15–24 years No JP 2000–2015 0.2 (-6.2; 7.2) 0.9
25–64 years No JP 2000–2015 4.2 (-2.9: 11.8) 0.2
≥65 years No JP 2000–2015 -4.5 (-12.3; 3.9) 0.3
IMD invasive meningococcal diseases, APC annual percent change, CI
confidence interval, JP joinpoint
Table 4 Findings of the joinpoint regression for IPD by age
group
Age group Joinpoint Years Range APC (95% CI) p-value
All age groups No JP 2000–2015 0.7 (-0.6; 2.1) 0.3
<1 year 2004 2000–2004 15.5 (-25.5; 78.9) 0.5
2004–2015 -16.7 (-28; -3.6) < 0.0001
1–4 years No JP 2000–2015 -7 (-13.7; 0.2) 0.1
5–9 years No JP 2000–2015 0.8 (-9.5; 12.2) 0.9
10–14 years 2002 2000–2002 81.9 (79.6; 84.3) < 0.0001
2009 2002–2009 -20.4 (-20.6; -20.2) < 0.0001
2012 2009–2012 99 (96.4; 101.6) < 0.0001
2012–2015 -50.1 (-50.4; -49.7) < 0.0001
15–24 years 2003 2000–2003 95.2 (-50.5; 670.3) 0.3
2003–2015 -13.4 (-22.5; -3.3) < 0.0001
25–64 years No JP 2000–2015 0.8 (-1.8; 3.5) 0.5
≥65 years No JP 2000–2015 1.7 (-0.5; 3.8) 0.1
IPD invasive pneumococcal diseases, APC annual percent change, CI
confidence interval, JP joinpoint
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older age (≥65 years old) associated to a higher risk of
dying (OR 3.13; 95% CI 1.14; 8.60) compared to adults
(18–64 years old). As for the IPD model, adults and eld-
erly (OR 17.43; 95% CI 2.40; 126.35) and patients with
comorbidities (OR 1.45; 95% CI 1.03; 2.04) had a higher
risk of death compared to patients in pediatric age and
without comorbidities respectively. Similarly, to IMD,
the model for invasive H. influenzae diseases was en-
tirely explained by the variable age: elderly (≥65 years
of age) showed a higher risk of death (OR 17.94; 95%
CI 2.16; 148.71).
Discussion
This historical observational study assessed the trends of
IBD hospitalizations in a population of 3.7 million people
over the past 16 years. The findings highlighted decreasing
hospitalization rates for IPD in infants <1 year of age,
likely because of the effects of PCV vaccines. A similar
reduction in S. pneumoniae-related hospitalizations in
children was shown in two other Italian regions, Friuli
Venezia Giulia and Veneto [17]. Although data were lim-
ited, high PCV vaccination coverages retrieved for 2013–
2015 support the conclusion. The data showed that, in the
last few years, hospitalization rates for invasive H. influen-
zae diseases increased, as also reported by the National
Surveillance System over the past 4 years. In fact, an in-
creasing trend, although non-significant, was observed in
infant <1 year of age from 2008 onwards, and a signifi-
cantly increasing trend was shown in the 1–4 years age
group from 2005 onwards. One can speculate that this in-
crease was linked, among other reasons, to a drop in Hib
vaccination coverage. Thanks to the high vaccination
coverage reached in almost all Italian regions, cases attrib-
utable to serotype b, the only ones preventable by vaccin-
ation, are rare [26]. Nevertheless, the common belief that
invasive H. influenzae diseases have disappeared after the
introduction of the vaccine is not supported and should
go no further. In fact, on average, one case out of nine per
Table 5 Findings of the joinpoint regression for invasive H.
influenzae diseases by age group
Age group Joinpoint Years Range APC (95% CI) p-value
All age groups No JP 2000–2015 -1.5 (-5.3; 2.4) 0.4
<1 year 2008 2000–2008 -17.5 (-30.5; -2.1) < 0.0001
2008–2015 10.8 (-12.9; 40.9) 0.4
1–4 years 2002 2000–2002 21.5 (-64.4; 314.2) 0.7
2005 2002–2005 -44.4 (-92.5; 312.1) 0.5
2005–2015 13.3 (0.0; 28.3) < 0.0001
5–9 years 2008 2000–2008 7.6 (-1.3; 17.2) 0.1
2008–2015 -15.1 (-24.0; -5.1) < 0.0001
10–14 years 2003 2000–2003 17.2 (16.5; 18.0) < 0.0001
2009 2003–2009 -9.8 (-10.0; -9.5) < 0.0001
2012 2009–2012 23.4 (21.9; 24.9) < 0.0001
2012–2015 -20.6 (-21.1; -20.1) < 0.0001
15–24 years 2003 2000–2003 -19.3 (-30.4; -6.5) < 0.0001
2003–2015 -0.1 (-2.1; 2.0) 0.9
25–64 years No JP 2000–2015 -0.7 (-7.9; 7.1) 0.8
≥65 years No JP 2000–2015 -1.4 (-7.1; 4.6) 0.6
APC annual percent change, CI confidence interval, JP joinpoint
Table 6 Findings of univariable analyses performed by chi-square test
Variable IMD IPD Invasive H. influenzae diseases
Dead n (%) Alive n (%) p-value Dead n (%) Alive n (%) p-value Dead n (%) Alive n (%) p-value
Age group
<5 years 5 (16.1) 81 (27.1) 0.004 0 (0.0) 81 (8.4) < 0.0001 1 (7.1) 15 (13.5) 0.003
5–17 years 4 (12.9) 63 (21.1) 1 (0.6) 30 (3.1) 0 (0.0) 7 (6.3)
18–64 years 11 (35.5) 124 (41.5) 39 (24.1) 397 (41.1) 0 (0.0) 41 (36.9)
≥65 years 11 (35.5) 31 (10.4) 122 (75.3) 459 (47.4) 13 (92.9) 48 (43.2)
Gender
male 10 (32.3) 145 (48.5) 0.085 77 (47.5) 514 (53.1) 0.185 7 (50.0) 61 (55.0) 0.726
female 21 (67.7) 154 (51.5) 85 (52.5) 453 (46.9) 7 (50.0) 50 (45.0)
Nationality
Italian 29 (96.7) 278 (93.6) 1.000 160 (98.8) 919 (95.4) 0.052 14 (100.0) 109 (98.2) 1.000
non-Italian 1 (3.3) 19 (6.4) 2 (1.2) 44 (4.6) 0 (0.0) 2 (1.8)
Charlson Index
0 23 (74.2) 269 (90.0) 0.014 88 (54.3) 643 (66.5) 0.004 6 (42.9) 64 (57.7) 0.090
1 7 (22.6) 19 (6.3) 41 (25.3) 153 (15.8) 1 (7.1) 22 (19.8)
2 1 (3.2) 11 (6.7) 33 (20.4) 171 (17.7) 7 (50.0) 25 (22.5)
IMD invasive meningococcal diseases, IPD invasive pneumococcal diseases
Chiappini et al. BMC Infectious Diseases  (2018) 18:396 Page 7 of 11
year (11.1%) occurred in children <4 years of age in 2012–
2015. Overall, HRs for IPD were in line with national esti-
mates, whereas HRs for invasive H. influenzae diseases, al-
though in line with estimates reported by some Italian
regions, were higher than national estimates presumably
affected by underreporting [26]. A more complex situation
emerged for IMD, whose HRs appeared to be, on average,
higher than the national ones (0.6 per 100,000 vs 0.3 per
100,000) [26], with two high peaks in 2004–2005 and in
2015. Considering that the time-trend analysis also re-
vealed joinpoints around those years, we can assume
two crucial changes in the epidemiology of IMD in
Tuscany. The first likely reflects the introduction of
MCC vaccine in 2005 with ensuing reduction of hospi-
talizations especially in children from 1 to 4 years of
age (although non-significant) and in adolescents from
10 to 14 years of age, both primary targets of the vac-
cination campaign. These findings were also in line
with a recent time-trend analysis investigating the im-
pact of the MCC vaccine introduction in Italy [39].
Nevertheless, not enough data on vaccination coverage
were available and thus no relationship could be deter-
mined in changes in age-specific HRs in relation to
vaccination. The second change is in line with the
increasing number of cases reported in young adults by
the National Surveillance System in 2015 and in the
first quarter of 2016 [26]. This change was also seen in
our data (in particular regarding the 15–24 years age
group) with nine and three cases respectively compared
to one case per year in the previous 2 years (data not
shown). This brought to the implementation of extraor-
dinary measures and to vaccinate, free of charge, people
Table 7 Findings of multivariable logistic regression models
Type of IBD Variable OR (95% CI) p-value
IMD (N = 330; p < 0.05; R2 = 0.07) Age group
<5 years 0.76 (0.25; 2.30) 0.624
5–17 years 0.79 (0.24; 2.61) 0.696
18–64 years 1.00
≥65 years 3.13 (1.14; 8.60) 0.027
Gender
male 0.70 (0.30; 1.62) 0.410
female 1.00
Charlson Index
no comorbidities 1.00
comorbidities 1.58 (0.56; 4.42) 0.385
IPD (N = 1125; p < 0.001; R2 = 0.04) Age group
<18 years 1.00
≥18 years 17.43 (2.40; 126.35) 0.005
Gender
male 0.81 (0.58; 1.13) 0.217
female 1.00
Nationality
Italian 3.38 (0.80; 14.20) 0.097
non-Italian 1.00
Charlson Index
no comorbidities 1.00
comorbidities 1.45 (1.03; 2.04) 0.031
Invasive H. influenzae diseases (N = 125; p < 0.001; R2 = 0.16) Age group
<65 years 1.00
≥65 years 17.94 (2.16; 148.71) 0.007
Charlson Index
no comorbidities 1.00
comorbidities 0.87 (0.26; 2.92) 0.821
IBD invasive bacterial disease, OR odds ratio, CI confidence interval, IMD invasive meningococcal diseases, IPD invasive pneumococcal diseases
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between 20 and 45 years of age and, under request and
with co-payment, people above 45 years of age [28, 29].
It is important to note that, although no death oc-
curred, 25 of the 330 IMD cases (7.6%) affected infants
<1 year and that the trend of HR for this age group was
the only positive one in the pediatric age (although
non-significant). In Tuscany, as well as in other Italian
regions, infants <1 years of age are not covered by the
MCC vaccination that is offered at 13th months of age.
The introduction of MenB vaccine for infants from
2014 onward can be expected to produce some benefits
in years to come.
Regarding IBDs in adults, a note on IMD is warranted.
Although the increased number observed in 2015–2016
has been mainly registered in young adults, adults from
25 to 64 years old contributed with half of the total cases
per year: 16 cases in 2015 and six in the first quarter of
2016 as compared to three cases per year in the previous
2 years (data not shown). Time-trend analysis for this
age group showed a positive but non-significant trend.
Attention should be paid to this fast-changing situation
also considering that adults above 45 years of age are
not strictly a target of extraordinary MCC vaccination
measures.
A deeper analysis is needed for the elderly. Despite the
decreasing trend in IBD in vaccinated children (direct
effect) and in unvaccinated subjects of all ages (indirect
effect) [40–43], the level of disease control in the elderly
is suboptimal. In fact, although no time-trends were ob-
served, the absolute number of cases and CFRs remain
high for all three IBD. For example, 42 of the 330 IMD
cases (12.7%) occurred in people ≥65 years old, contrib-
uting with the highest number of deaths (11 out of 31
deaths due to IMD). This would appear even more rele-
vant looking at invasive H. influenzae diseases: 61 out of
the 125 cases (49%) were registered in elderly as well as
all deaths except one. The age-specific CFRs were higher
than European estimates reported by the European
Centre for Disease Prevention and Control (ECDC) [1]:
26.2% vs 17.1% for IMD, 21% vs 14.3% for IPD, and
21.3% vs 15% for invasive H. influenzae diseases. Fur-
thermore, in all three regression models, older age was
significantly associated with a higher risk for death. Sev-
eral studies in the literature found older age and Charl-
son comorbidities to be independent predictors of death
[44, 45]. This evidence calls for actions to extend out
high vaccination coverage in elderly and people with
chronic conditions to prevent the occurrence of such
IBD, in particular IPD, in these groups.
In fact, while MCC and Hib vaccines are not given to
the elderly, the 23-valent pneumococcal polysaccharide
vaccine (PPV23) first and then the PCV13 have been
used in Italy in people ≥65 years of age. Nevertheless,
albeit data on adults vaccination coverage are not
routinely collected, local or regional studies suggest that
vaccination coverage in people ≥65 years of age is quite
low, varying from 0.7 to 50% between 2004 and 2008
[22], when the PPV23 was administered to elderly [46].
A recently concluded randomized trial in the Netherlands
provide the missing evidence of PCV13 efficacy in pre-
venting vaccine-type IPD in older adults [47]. This
evidence, together with an increased awareness of the
problem of IBD in the elderly, should support policy
makers in their decisions on the implementation of
pneumococcal vaccination. This is envisaged also because
vaccinating elderly against S. pneumoniae may prevent
not only IPD but also pneumonia, which causes 1 million
hospitalizations in Europe, costs about €10 billion per
year, and represents the most frequent cause of death
from infection [48, 49].
A positive point of the present study is that it gives a
thorough overview of the epidemiology of IBD yielding
also CFRs. This measure is widely used as an outcome
indicator to make comparisons over time and between
areas as its calculation is less prone to bias [50]. Moreover,
compared to the National Surveillance System which in-
cluded invasive diseases since 2007 only [22], this study
was able to provide a picture of IBD over a wider time
window overcoming the apparent increase in the number
of cases which occurred in the National Surveillance
System. Our study presents also some limitations. One is
concerning the general sparse-cells problem that makes
joinpoint models unstable and may justify fluctuating
positive and negative trends in children from 10 to
14 years of age both for IPD and invasive H. influenzae dis-
eases. Furthermore, it should be kept in mind that in pres-
ence of zero-counts, small absolute fluctuation may have a
great relative impact. Another limitation was the lack of
information on death after discharge from the hospital or
transfer to a private non-accredited institute even though
we consider it improbable to affect our results as the
number of transferred patients was very low. Another
limitation is represented by the lack of information on
serotype distribution and individual vaccination records
that could have allowed a more in-depth analysis of the
relationship between vaccination and the occurrence of
diseases. Additionally, over the past 16 years, diagnostics
methods have become more sensitive and life support
techniques could have influenced the health outcome.
Finally, R-square values of regression models were very
low, ranging between 4 and 16% because of the limited
number of variables available from the hospital discharge
records.
In conclusion, the results of our study contribute to
the body of evidence on the epidemiology of IBD and
the importance of ensuring high vaccination coverage. A
constant effort should be made to attain and maintain
high vaccination coverage among children in order to
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further reduce the incidence of all IBD and control ap-
parent increasing trends. In particular, attention should
be paid to the increase in invasive H. influenzae diseases
and to the changing epidemiological scenario of IMD.
Furthermore, actions should be also promoted to imple-
ment vaccination in the elderly. Eventually, prevention
remains the most valuable tool to help reducing the
burden of IBD in all age groups.
Conclusion
This study shows changes in the epidemiology of IBD,
particularly due to H. influenzae and N. meningitidis,
and high rates of hospitalizations and deaths for all types
of IBD in elderly. This evidence calls for actions in order
to maintain high vaccination coverage among children
and promote vaccination in older age groups.
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